Quotient Sciences
- Company typePrivate
- Founded2004
- HeadquartersNottingham, United Kingdom
- Headcount251–500
- GTM typeB2B
- OfferingServices
Quotient Sciences firmographics
Firmographics- Name
- Quotient Sciences
- Legal name
- Quotient Sciences
- Website
- https://www.quotientsciences.com/
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Quotient Sciences industry classification
Industry- Product category
- Contract Pharmaceutical Development and Manufacturing (CRDMO)
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Pharmaceutical Preparation Manufacturing (325412), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- CMC, Process Development & Tech Transfer Staffing FSP (HLAGAOAK)
- akta.pro secondary industries
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Clinical Trial Supply, Logistics & Vendor Management FSP (HLAGAOAH), Manufacturing, MSAT & Operations Staffing (API/Biologics/Cell & Gene) (HLAGAOAL)
Keywords
Where Quotient Sciences is headquartered
LocationHeadquarters
- HQ city
- Nottingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices6 records
Markets served
Quotient Sciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- CRDMO Contract Services: Integrated contract services spanning drug substance manufacturing, drug product development, and clinical trial services. Revenue generated through project-based contracts with pharmaceutical and biotech companies.
- Clinical Development Services: Phase I clinical trials, clinical pharmacology studies, and bioanalysis services billed through project contracts.
- Commercial Manufacturing: Manufacturing services for approved products including commercial supply agreements such as the Ipsen partnership for Sohonos (palovarotene).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Quotient Sciences product offering
Product offeringCore offering
Quotient Sciences is a CRDMO (Contract Research, Development, and Manufacturing Organization) providing integrated pharmaceutical development services. Its flagship Translational Pharmaceutics platform combines formulation development, cGMP manufacturing, and clinical testing under a single project management team. Supporting services include Phase I early clinical development, formulation development, human ADME studies, commercial drug product manufacturing, and data sciences.
Product overview
Quotient Sciences is a CRDMO (Contract Research, Development, and Manufacturing Organization) providing integrated pharmaceutical development services. The core offering is the Translational Pharmaceutics® platform, which uniquely integrates formulation development, GMP manufacturing, and clinical testing under single project management. Supporting services include Early Clinical Development (Phase I trials), Formulation Development, Human ADME Studies (via Synthesis-to-Clinic®), Pharmacy Compounding, Data Sciences, and Commercial Manufacturing. AI capabilities are being integrated through the ANDROMEDA machine learning platform partnership with Intrepid Labs for formulation optimization.
Differentiator
Problem solved
Functional benefit
Brands
- Translational Pharmaceutics®: Integrated drug development platform combining formulation development, GMP manufacturing, and clinical testing under single project management for accelerated timelines.
- Synthesis-to-Clinic®
Products and services
- Translational Pharmaceutics
Quantifiable outcome
- 1,300+ Phase I studies delivered
- +2 more outcomes
Companies that use Quotient Sciences
Customer profileNamed customers12 records
Segments3 records
Ideal customer profiles3 records
Quotient Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Quotient Sciences partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Intrepid LabscoreMulti-year strategic partnership to integrate Intrepid Labs' ANDROMEDA AI platform into Quotient Sciences' formulation development processes. This collaboration enhances AI-guided formulation development capabilities, enabling accelerated optimization of drug formulations using machine learning algorithms.
- Lindus HealthcoreStrategic partnership providing integrated clinical development pathways combining Quotient Sciences' Translational Pharmaceutics and manufacturing capabilities with Lindus Health's clinical trial expertise. Aims to streamline drug development from preclinical through Phase II studies.
- BiorasicoreStrategic partnership delivering integrated early phase clinical trial solutions. Combines Biorasi's global clinical operations expertise with Quotient Sciences' formulation development and manufacturing capabilities for seamless early-stage development programs.
- IpsencoreCommercial manufacturing partnership for Sohonos (palovarotene), a treatment for fibrodysplasia ossificans progressiva. Quotient Sciences manufactures and supplies commercial product for the approved therapy.
- IRIS Technology SolutionsminorParticipation in the Horizon Europe-funded ETERNAL project focused on advanced pharmaceutical manufacturing technologies. Collaboration with IRIS Technology Solutions and other partners on process innovation.
- CPI (Centre of Process Innovation)minorJoint venture focused on mRNA therapeutics development and manufacturing. Combines Quotient Sciences' pharmaceutical development expertise with CPI's process innovation capabilities for next-generation nucleic acid medicines.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
Quotient Sciences competitors and assessment
Company assessmentDirect peers
- Medpace: Medpace is a mid-sized clinical CRO focused on full-service clinical development for small to mid-sized biopharma. Comparable to Quotient Sciences on the early clinical development and Phase I service overlap, with similar mid-tier positioning relative to mega-CROs, though Medpace lacks drug product manufacturing capabilities.
- Recipharm: Recipharm is a European CDMO offering drug substance and drug product development and manufacturing services. Compares to Quotient Sciences on formulation development and contract manufacturing capabilities, with similar mid-tier positioning, though Recipharm's portfolio is more weighted toward commercial manufacturing.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO specializing in early-phase clinical development, bioanalysis, and Phase II/III studies. Direct peer to Quotient Sciences on Phase I clinical pharmacology and early-phase clinical services, with similar mid-market positioning focused on complex and rare disease programs.
Broad incumbents
- ICON plc: ICON plc is a leading global CRO providing Phase I-IV clinical development, bioanalytical, and consulting services. Compares to Quotient Sciences on early clinical development and Phase I clinical pharmacology services, though ICON's portfolio extends well beyond early-phase into late-stage and post-approval studies.
- Lonza Group: Lonza is a Swiss-based global CDMO providing drug substance and drug product services across small molecules, biologics, and cell/gene therapy. Compares to Quotient on the contract manufacturing and formulation development side, though it operates at far greater scale with a much wider service portfolio including biologics.
- IQVIA: IQVIA is the world's largest CRO offering clinical trial services, laboratory services, and real-world evidence. Comparable to Quotient Sciences on Phase I clinical pharmacology and bioanalysis services, though IQVIA's scope spans the full clinical lifecycle and operates at vastly larger scale.
- WuXi AppTec: WuXi AppTec is a Chinese-headquartered global CRDMO providing drug discovery, development, and manufacturing services. Comparable to Quotient Sciences on integrated CRDMO offerings, formulation development, and clinical services, though it operates at substantially larger scale with broader geographic reach across Asia and beyond.
- Catalent: Catalent (now owned by Novo Holdings) is a global CDMO with extensive formulation development, clinical supply, and commercial manufacturing services. Compares to Quotient Sciences across drug product development and manufacturing, but operates at significantly larger scale with a broader service portfolio across biologics, softgel, and oral technologies.
- Thermo Fisher Scientific (CDMO services): Thermo Fisher Scientific's PPD CDMO business provides end-to-end drug substance, drug product, and clinical development services following its acquisition of Patheon. Comparable to Quotient Sciences on integrated CDMO offerings, though at substantially larger scale with broader scientific and operational capabilities.
- Charles River Laboratories: Charles River Laboratories offers preclinical, clinical, and manufacturing services to pharma/biotech. Comparable to Quotient on the early-phase clinical and CDMO side, with overlapping capabilities in drug substance and drug product development, though substantially larger in scale and broader in scientific scope.
Market position
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Quotient Sciences social profiles
Digital presenceQuotient Sciences compliance and trust
Trust signalCompliance5 records
Quotient Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quotient Sciences leadership team
Management profileNumber of profiles
Profiles12 records
Quotient Sciences subsidiaries and ownership
Company hierarchySubsidiaries3 records
Quotient Sciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quotient Sciences M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quotient Sciences
What does Quotient Sciences do?
Quotient Sciences is a CRDMO (Contract Research, Development, and Manufacturing Organization) providing integrated pharmaceutical development services. Its flagship Translational Pharmaceutics platform combines formulation development, cGMP manufacturing, and clinical testing under a single project management team. Supporting services include Phase I early clinical development, formulation development, human ADME studies, commercial drug product manufacturing, and data sciences.
Is Quotient Sciences a public or private company?
Quotient Sciences is a private company. It is classified as private equity controlled and is currently operating.
When was Quotient Sciences founded?
Quotient Sciences was founded in 2004. It employs 251 to 500 people.
Where is Quotient Sciences based?
Quotient Sciences is headquartered in Nottingham, United Kingdom, in the Europe region.
How does Quotient Sciences make money?
Three revenue lines are on record. CRDMO Contract Services are the primary driver. The others are clinical Development Services and commercial Manufacturing.
Who are Quotient Sciences's main competitors?
Direct peers on record are Medpace, Recipharm and Worldwide Clinical Trials. Broad incumbents are ICON plc, Lonza Group, IQVIA, WuXi AppTec, Catalent, Thermo Fisher Scientific (CDMO services) and Charles River Laboratories.
Does Quotient Sciences have an API?
No public API is recorded for Quotient Sciences.
What industry is Quotient Sciences in?
Quotient Sciences's product category is Contract Pharmaceutical Development and Manufacturing (CRDMO). Its primary akta.pro industry code is HLAGAOAK, CMC, Process Development & Tech Transfer Staffing FSP, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 5417 and its SIC code is 8731.